Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
about
Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritisLevels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis.The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseasesPituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelaeEffects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusionPituitary Adenylate Cyclase-Activating Polypeptide Reverses Ammonium Metavanadate-Induced Airway Hyperresponsiveness in RatsVasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses.Activation of cyclic adenosine monophosphate-dependent protein kinase a signaling prevents liver ischemia/reperfusion injury in miceVPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP.Neural networks in intestinal immunoregulationRoflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.PACAP in immunity and inflammation.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.Proliferative enteropathy (PE)-induced changes in the calbindin-immunoreactive (CB-IR) neurons of inferior mesenteric ganglion supplying the descending colon in the pig.Tuning inflammation with anti-inflammatory neuropeptides.Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersVIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repairEndogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.Cyclic AMP: a selective modulator of NF-κB action.Mucosal macrophages in intestinal homeostasis and inflammation.PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.Vasoactive intestinal peptide enhances TNF-α-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-κB-dependent mechanism.Induction of latency-associated peptide (transforming growth factor-β(1)) expression on CD4+ T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-α production in a transforming growth factor-β-dependent manner.Effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on IL-6, IL-8, and MCP-1 expression in human retinal pigment epithelial cell line.Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP.VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.Pituitary adenylate cyclase-activating polypeptide deficiency enhances oxazolone-induced allergic contact dermatitis in mice.Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.PACAP attenuates NMDA-induced retinal damage in association with modulation of the microglia/macrophage status into an acquired deactivation subtype.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro.Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide.PACAP38 suppresses cortical damage in mice with traumatic brain injury by enhancing antioxidant activity.Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells.Inflammation-induced changes in the chemical coding pattern of colon-projecting neurons in the inferior mesenteric ganglia of the pig.Changes of PACAP immunoreactivities and cytokine levels after PACAP-38 containing intestinal preservation and autotransplantation.PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma.
P2860
Q24795258-2645345E-BF87-4F84-9946-77749156E346Q24816519-243F19D9-F044-4ABC-948B-1B47AC58D74CQ26851670-755D1E43-BFFB-429C-9230-4B631B217CB4Q27345033-8AA1250A-57A5-4BA6-9C28-A469052EC060Q28580766-09ABF6A3-6229-4B6C-9E61-90429BA52D10Q28647317-2CD2AF52-CB49-40B9-9802-7D26E684A548Q34238010-7F71D269-BB44-41E1-9743-6A03BFB10428Q34277527-AA0894B9-42F8-4A1C-B62D-714E93CC1D7FQ34292003-9ADE1288-7145-406B-893A-A1F93882CA1AQ34765538-0BD31BDD-73E7-4BD3-80EB-BD03192480BCQ34789781-FEA8EC6C-A99E-4353-9A74-EA008E527FDBQ34836430-C5796948-43E9-4275-B776-89017EE347B2Q34997388-E5F4208A-139C-41E1-B351-EDF626FAB5C3Q35148499-8BF30AF6-1191-405D-BDDA-65699670A321Q35295564-1AC633B0-26FF-4BD7-B2AF-C1E251225B39Q36025380-4D3A28DF-A69B-4117-9535-EFEFB478711BQ36247760-D9376A10-D9EF-438F-89EB-36530CBB2519Q36764912-D8E6C152-0685-4CA2-9628-5CDCBCF9DAD9Q36830470-B5B7B857-5D6A-47E0-AE8D-EA825B90D923Q36929423-69E3A376-DFAF-4225-8235-ED21FEC5CA5BQ37191369-B03AEA53-C866-4919-B9AF-771B3B7CB4A7Q37899788-B3076C30-3363-4633-AD41-A5A0820BE6DFQ37949275-A453675D-89DC-4047-A21D-0E7E23407D6FQ39003365-B9C1B42E-C578-4504-A7ED-EA9A90ACF43BQ39420647-CFAA82C6-D777-449B-9DEF-133F7D00B3E1Q39572367-5C9B26D4-68CF-4939-99F3-96EC891566F6Q40340052-4769049E-15ED-423E-97DF-915F1236F172Q41884883-89993CC1-3865-4A2A-BF6F-52D30E34ADE0Q42329973-6033D3CC-64C1-47EF-BA43-763A677B79A7Q43087837-6B0E44F6-8B80-4D64-948C-E1785F6E46EAQ43297260-360ED8BE-0369-44A5-A1C8-579F053B1248Q43873491-9C61CC65-1B34-4C85-B948-DF0A8EB5C82DQ44060393-CB33EF22-0107-4DCE-BD3C-006511A51FF3Q46059692-C61FF86D-9693-4A5F-90A1-E9B0C7D34538Q46875236-B97E8BCC-3963-47ED-B692-9E68DFCE190FQ46882701-34653CBE-58F0-47B1-BE9B-7F2070971716Q48004175-DF967F5B-173B-44A3-B53D-C90312DD0966Q48240143-34CF870F-0D0B-496F-9AEB-74B79D2492C9Q50919115-28507903-0E18-45BA-AB05-B49FB0E53ECEQ52656846-D5EFA2E8-ADB4-434E-9563-5D4BF9219124
P2860
Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Inhibition of endotoxin-induce ...... ypeptide in vitro and in vivo.
@en
type
label
Inhibition of endotoxin-induce ...... ypeptide in vitro and in vivo.
@en
prefLabel
Inhibition of endotoxin-induce ...... ypeptide in vitro and in vivo.
@en
P1476
Inhibition of endotoxin-induce ...... ypeptide in vitro and in vivo.
@en
P2093
P304
P356
10.4049/JIMMUNOL.167.2.966
P407
P577
2001-07-01T00:00:00Z